The toxicological evaluation of tallysomycin s10b--biosynthetic tallysomycin derivative. 1984

R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf

Tallysomycin S10b, a biosynthetic derivative of tallysomycin B, was subjected to intravenous toxicologic studies in mice and dogs. LD50 and LD10 values from lethality studies in mice were utilized to establish dose levels for single and five daily dose toxicity studies in mice and dogs. Nephrotoxicity was the most consistent and prominent drug-related alteration in single and multiple dose studies in both species and was considered the dose limiting toxicity. Other toxicities included pulmonary toxicity, lymphopenia and necrosis of extremities in mice and dogs and testicular degeneration and focal vacuolation of adrenal cortical cells in the dog. Bleomycin was administered to dogs as a reference control agent at a single dose of 270 mg/m2 which was approximately equivalent to the highest tallysomycin S10b dose of 240 mg/m2. Tallysomycin S10b showed a greater nephrotoxic potential than bleomycin at earlier time periods. However, at termination there was no meaningful difference in the degree of chronic nephrotoxicity. The pulmonary toxicity of both drugs was comparable.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008297 Male Males
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
June 1981, The Journal of antibiotics,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
January 1989, Cancer chemotherapy and pharmacology,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
January 1984, Cancer chemotherapy and pharmacology,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
May 1990, Investigational new drugs,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
January 1986, Cancer chemotherapy and pharmacology,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
October 1991, Nuklearmedizin. Nuclear medicine,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
January 1990, Cancer chemotherapy and pharmacology,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
March 1989, Cancer research,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
August 1990, Investigational new drugs,
R A Buroker, and C R Comereski, and D Barnett, and R S Hirth, and H Madissoo, and G H Hottendorf
February 1992, Cancer research,
Copied contents to your clipboard!